



## Krabbe disease

Krabbe disease (also called globoid cell leukodystrophy) is a severe neurological condition. It is part of a group of disorders known as leukodystrophies, which result from the loss of myelin (demyelination) in the nervous system. Myelin is the protective covering around nerve cells that ensures the rapid transmission of nerve signals. Krabbe disease is also characterized by abnormal cells in the brain called globoid cells, which are large cells that usually have more than one nucleus.

The most common form of Krabbe disease, called the infantile form, usually begins before the age of 1. Initial signs and symptoms typically include irritability, muscle weakness, feeding difficulties, episodes of fever without any sign of infection, stiff posture, and delayed mental and physical development. As the disease progresses, muscles continue to weaken, affecting the infant's ability to move, chew, swallow, and breathe. Affected infants also experience vision loss and seizures. Because of the severity of the condition, individuals with the infantile form of Krabbe disease rarely survive beyond the age of 2.

Less commonly, Krabbe disease begins in childhood, adolescence, or adulthood (late-onset forms). Vision problems and walking difficulties are the most common initial symptoms in these forms of the disorder, however, signs and symptoms vary considerably among affected individuals. Individuals with late-onset Krabbe disease may survive many years after the condition begins.

### Frequency

In the United States, Krabbe disease affects about 1 in 100,000 individuals. A higher incidence (6 cases per 1,000 people) has been reported in a few isolated communities in Israel.

### Genetic Changes

Mutations in the *GALC* gene cause Krabbe disease. This gene provides instructions for making an enzyme called galactosylceramidase, which breaks down certain fats called galactolipids. One galactolipid broken down by galactosylceramidase, called galactosylceramide, is an important component of myelin. Breakdown of galactosylceramide is part of the normal turnover of myelin that occurs throughout life. Another galactolipid, called psychosine, which is formed during the production of myelin, is toxic if not broken down by galactosylceramidase.

*GALC* gene mutations severely reduce the activity of the galactosylceramidase enzyme. As a result, galactosylceramide and psychosine cannot be broken down. Excess galactosylceramide accumulates in certain cells, forming globoid cells. The

accumulation of these galactolipids causes damage to myelin-forming cells, which impairs the formation of myelin and leads to demyelination in the nervous system. Without myelin, nerves in the brain and other parts of the body cannot transmit signals properly, leading to the signs and symptoms of Krabbe disease.

### **Inheritance Pattern**

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

### **Other Names for This Condition**

- diffuse globoid body sclerosis
- galactosylceramidase deficiency disease
- galactosylceramide lipidosis
- galactosylcerebrosidase deficiency
- galactosylsphingosine lipidosis
- GALC deficiency
- GCL
- GLD
- psychosine lipidosis

### **Diagnosis & Management**

#### Genetic Testing

- Genetic Testing Registry: Galactosylceramide beta-galactosidase deficiency  
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0023521/>

#### Other Diagnosis and Management Resources

- Baby's First Test  
<http://www.babysfirsttest.org/newborn-screening/conditions/krabbe>
- GeneReview: Krabbe Disease  
<https://www.ncbi.nlm.nih.gov/books/NBK1238>
- MedlinePlus Encyclopedia: Krabbe disease  
<https://medlineplus.gov/ency/article/001198.htm>
- United Leukodystrophy Foundation: Krabbe disease  
<http://ulf.org/krabbe-disease/>

### General Information from MedlinePlus

- Diagnostic Tests  
<https://medlineplus.gov/diagnostictests.html>
- Drug Therapy  
<https://medlineplus.gov/drugtherapy.html>
- Genetic Counseling  
<https://medlineplus.gov/geneticcounseling.html>
- Palliative Care  
<https://medlineplus.gov/palliativecare.html>
- Surgery and Rehabilitation  
<https://medlineplus.gov/surgeryandrehabilitation.html>

### **Additional Information & Resources**

#### MedlinePlus

- Encyclopedia: Krabbe disease  
<https://medlineplus.gov/ency/article/001198.htm>
- Health Topic: Leukodystrophies  
<https://medlineplus.gov/leukodystrophies.html>
- Health Topic: Newborn Screening  
<https://medlineplus.gov/newbornscreening.html>

#### Genetic and Rare Diseases Information Center

- Krabbe disease  
<https://rarediseases.info.nih.gov/diseases/6844/krabbe-disease>

#### Additional NIH Resources

- National Institute of Neurological Disorders and Stroke: Krabbe Disease  
<https://www.ninds.nih.gov/Disorders/All-Disorders/Krabbe-Disease-Information-Page>
- National Institute of Neurological Disorders and Stroke: Leukodystrophy  
<https://www.ninds.nih.gov/Disorders/All-Disorders/Leukodystrophy-Information-Page>
- National Institute of Neurological Disorders and Stroke: Lipid Storage Diseases  
<https://www.ninds.nih.gov/Disorders/All-Disorders/Lipid-storage-diseases-Information-Page>

### Educational Resources

- MalaCards: krabbe disease  
[http://www.malacards.org/card/krabbe\\_disease](http://www.malacards.org/card/krabbe_disease)
- Orphanet: Krabbe disease  
[http://www.orpha.net/consor/cgi-bin/OC\\_Exp.php?Lng=EN&Expert=487](http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=487)
- Tulane University  
<http://www2.tulane.edu/tnprc/diseases/krabbe/>

### Patient Support and Advocacy Resources

- Children Living with Inherited Metabolic Diseases  
<http://www.climb.org.uk>
- Hunter's Hope Foundation  
<https://huntershope.org/>
- National Organization for Rare Disorders  
<https://rarediseases.org/rare-diseases/leukodystrophy-krabbes/>
- United Leukodystrophy Foundation  
<http://ulf.org>

### GeneReviews

- Krabbe Disease  
<https://www.ncbi.nlm.nih.gov/books/NBK1238>

### ClinicalTrials.gov

- ClinicalTrials.gov  
<https://clinicaltrials.gov/ct2/results?cond=%22krabbe+disease%22>

### Scientific Articles on PubMed

- PubMed  
<https://www.ncbi.nlm.nih.gov/pubmed?term=%28Leukodystrophy,+Globoid+Cell%5BMAJR%5D%29+AND+%28Krabbe+disease%5BTIAB%5D%29+AND+english%5BIa%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D>

### OMIM

- KRABBE DISEASE  
<http://omim.org/entry/245200>

## Sources for This Summary

- Graziano AC, Cardile V. History, genetic, and recent advances on Krabbe disease. *Gene*. 2015 Jan 15;555(1):2-13. doi: 10.1016/j.gene.2014.09.046. Epub 2014 Sep 26. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/25260228>
- National Institute of Neurological Disorders and Stroke: Krabbe Disease  
<https://www.ninds.nih.gov/Disorders/All-Disorders/Krabbe-Disease-Information-Page>
- Sakai N. Pathogenesis of leukodystrophy for Krabbe disease: molecular mechanism and clinical treatment. *Brain Dev*. 2009 Aug;31(7):485-7. doi: 10.1016/j.braindev.2009.03.001. Epub 2009 Mar 29. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/19332366>
- Shin D, Feltri ML, Wrabetz L. Altered Trafficking and Processing of GALC Mutants Correlates with Globoid Cell Leukodystrophy Severity. *J Neurosci*. 2016 Feb 10;36(6):1858-70. doi: 10.1523/JNEUROSCI.3095-15.2016.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/26865610>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748072/>
- Spratley SJ, Hill CH, Viuff AH, Edgar JR, Skjødt K, Deane JE. Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants. *Traffic*. 2016 Aug;17(8):908-22. doi: 10.1111/tra.12404. Epub 2016 May 30.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/27126738>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949656/>
- Wenger DA, Rafi MA, Luzi P. Krabbe disease: One Hundred years from the bedside to the bench to the bedside. *J Neurosci Res*. 2016 Nov;94(11):982-9. doi: 10.1002/jnr.23743. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/27638583>
- Wenger DA. Krabbe Disease. 2000 Jun 19 [updated 2011 Mar 31]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from <http://www.ncbi.nlm.nih.gov/books/NBK1238/>  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/20301416>

---

Reprinted from Genetics Home Reference:

<https://ghr.nlm.nih.gov/condition/krabbe-disease>

Reviewed: January 2018

Published: January 16, 2018

Lister Hill National Center for Biomedical Communications

U.S. National Library of Medicine

National Institutes of Health

Department of Health & Human Services